Gynae BT 2017

Vaginal morbidity after definitive radiochemotherapy + IGABT in LACC

G≥1: 89%

• N=588 LACC within EMBRACE study • Prospective assessment of morbidity (CTCAE 3) at baseline and regular follow-ups (median 15 months) • Endpoints: vaginal stenosis, dryness, mucositis, bleeding, fistula

G≥2: 29%

G≥3: 4%

Kirchheiner et al. IJROBP 2014